Parasitic protozoa cause devastating diseases across large regions of the globe, but a lack of economic incentives has resulted in the limited development of drugs against these "neglected diseases." Transporters expressed in the plasma membranes of these parasites offer potential for the development of new drugs. These permeases could be employed in two distinct strategies for drug development: (i) targeting selective delivery of drugs to the parasite and (ii) developing drugs that inhibit essential parasite permeases.